Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902174 · ClinicalTrials.gov registry record · Phase 3
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT00902174: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00902174 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 202 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00902174, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
Primary Outcome
This standardized walk course was 30 meters in length. During the walk the participant was connected to a portable pulse oximeter via a finger probe. Participants were instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. The total distance walked (in meters) was recorded. Results were compared between the 2 groups.
Interventions
- DRUG Placebo
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00902174 record still lists
NCT00902174 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00902174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00902174 about?
NCT00902174 is a clinical study titled "Imatinib (QTI571) in Pulmonary Arterial Hypertension". A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
What is the current status of trial NCT00902174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2009-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00902174?
The interventions under investigation include: Placebo (DRUG), imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00902174?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00902174's enrollment target sits among peer trials
202 1353rd of 2000 higher than 648 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia